Systemic Lupus clinical trials

Explore recruiting systemic lupus clinical trials.

Recruiting systemic lupus studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Systemic Lupus trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obinutuzumab in Patients with Systemic Lupus Erythematosus

France, Poland, Italy, Czechia, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Randomised, placebo-controlled, double-blind, parallel-group Phase II study to evaluate the efficacy and safety of oral BI 3000202 in patients with moderate to severe systemic lupus erythematosus (SLE)

Bulgaria, Romania, Germany, Spain, Hungary, Poland +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized, double-blind, placebo-controlled extension study to assess the long-term safety and tolerability of ianalumab in patients with systemic lupus erythematosus (SIRIUS-SLE extension)

Romania, Poland, Hungary, Portugal, Italy, Slovakia +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

OPUS-2 - Oral S1P1 Receptor ModUlation in SLE: A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy

Spain, Germany, Portugal, Poland, Czechia

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Double-blind, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)

Germany, Romania, France, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

An open-label, multi-center, phase 1/2 study to assess safety, efficacy and cellular kinetics of YTB323 in participants with severe, refractory systemic lupus erythematosus (srSLE).

Spain, France, Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Systemic Lupus trials by city

Systemic Lupus in Toronto Systemic Lupus in Vancouver Systemic Lupus in Montreal Systemic Lupus in Calgary Systemic Lupus in Edmonton Systemic Lupus in Ottawa Systemic Lupus in Winnipeg Systemic Lupus in Quebec City Systemic Lupus in Hamilton Systemic Lupus in Kitchener Systemic Lupus in London Systemic Lupus in Halifax Systemic Lupus in New York Systemic Lupus in Los Angeles Systemic Lupus in Chicago Systemic Lupus in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease